Cohen Y - Search Results

1

Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations.

Mambo E, Gao X, Cohen Y, Guo Z, Talalay P, Sidransky D. Mambo E, et al. Among authors: cohen y. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43. doi: 10.1073/pnas.0437910100. Epub 2003 Feb 10. Proc Natl Acad Sci U S A. 2003. PMID: 12578990 Free PMC article.

2

BRAF mutation in papillary thyroid carcinoma.

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. Cohen Y, et al. J Natl Cancer Inst. 2003 Apr 16;95(8):625-7. doi: 10.1093/jnci/95.8.625. J Natl Cancer Inst. 2003. PMID: 12697856

3

Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.

Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D. Xing M, et al. Among authors: cohen y. Cancer Res. 2004 Mar 1;64(5):1664-8. doi: 10.1158/0008-5472.can-03-3242. Cancer Res. 2004. PMID: 14996725

4

The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection.

Maitra A, Cohen Y, Gillespie SE, Mambo E, Fukushima N, Hoque MO, Shah N, Goggins M, Califano J, Sidransky D, Chakravarti A. Maitra A, et al. Among authors: cohen y. Genome Res. 2004 May;14(5):812-9. doi: 10.1101/gr.2228504. Genome Res. 2004. PMID: 15123581 Free PMC article.

5

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. Begum S, et al. Among authors: cohen y. Mod Pathol. 2004 Nov;17(11):1359-63. doi: 10.1038/modpathol.3800198. Mod Pathol. 2004. PMID: 15195111 Free article.

6

Mitochondrial DNA content increase in response to cigarette smoking.

Masayesva BG, Mambo E, Taylor RJ, Goloubeva OG, Zhou S, Cohen Y, Minhas K, Koch W, Sciubba J, Alberg AJ, Sidransky D, Califano J. Masayesva BG, et al. Among authors: cohen y. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):19-24. doi: 10.1158/1055-9965.EPI-05-0210. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16434581

7

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IeM. Singer G, et al. Among authors: cohen y. J Natl Cancer Inst. 2003 Mar 19;95(6):484-6. doi: 10.1093/jnci/95.6.484. J Natl Cancer Inst. 2003. PMID: 12644542

8

Lack of BRAF mutation in primary uveal melanoma.

Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J, Sidransky D. Cohen Y, et al. Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2876-8. doi: 10.1167/iovs.02-1329. Invest Ophthalmol Vis Sci. 2003. PMID: 12824225

9

The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.

Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D. Cohen Y, et al. Clin Cancer Res. 2003 Aug 1;9(8):2981-4. Clin Cancer Res. 2003. PMID: 12912945

10

Colorimetric approach to high-throughput mutation analysis.

Benoit NE, Goldenberg D, Deng SX, Rosenbaum E, Cohen Y, Califano JA, Shackelford WH, Wang XB, Sidransky D. Benoit NE, et al. Among authors: cohen y. Biotechniques. 2005 Apr;38(4):635-9. doi: 10.2144/05384PF01. Biotechniques. 2005. PMID: 15884682 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,892 results

Search Page